# Prescription Drug Policy: Resources

This section provides a curated list of key research, government reports, data sources, and organizations relevant to prescription drug policy reform.

---

## Academic Research

### Peer-Reviewed Studies

- Wen, H., Hockenberry, J. M., & Cummings, J. R. "The Effect of Medicaid Expansion on Crime Reduction: Evidence from HIFA-Waiver Expansions." *Journal of Public Economics* 154 (2017): 67-94.
- Buchmueller, T. C., & Carey, C. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare." *American Economic Journal: Economic Policy* 10, no. 1 (2018): 77-112.
- Pardo, B. "Do More Robust Prescription Drug Monitoring Programs Reduce Prescription Opioid Overdose?" *Addiction* 112, no. 10 (2017): 1773-1783.
- Mallatt, J. "The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates." *Journal of Health Economics* 73 (2020): 102356.
- DeJong, C., et al. "Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries." *JAMA Internal Medicine* 176, no. 8 (2016): 1114-1122.
- Wouters, O. J., McKee, M., & Luyten, J. "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." *JAMA* 323, no. 9 (2020): 844-853.
- Cleary, E. G., et al. "Contribution of NIH Funding to New Drug Approvals 2010-2016." *Proceedings of the National Academy of Sciences* 115, no. 10 (2018): 2329-2334.
- Nuckols, T. K., et al. "The Effectiveness of Computerized Order Entry at Reducing Preventable Adverse Drug Events and Medication Errors in Hospital Settings: A Systematic Review and Meta-analysis." *Annals of Internal Medicine* 160, no. 4 (2014): 271-280.
- Lin, L. A., et al. "Impact of the Opioid Safety Initiative on Opioid-Related Prescribing in Veterans." *JAMA Internal Medicine* 177, no. 12 (2017): 1838-1845.

### Working Papers and White Papers

- RAND Corporation. "International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies." Working Paper RR-2956-ASPEC. 2024.
- Congressional Budget Office. "Estimated Budgetary Effects of the Inflation Reduction Act's Drug Provisions." CBO Working Paper. 2024.
- Drug Channels Institute. "The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers." 2024.
- I-MAK. "Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies and Driving Up Drug Prices." 2024.

---

## Government Reports and Data

### Federal Agencies

- Centers for Disease Control and Prevention. "U.S. Opioid Dispensing Rate Maps." Updated annually. <https://www.cdc.gov/drugoverdose/rxrate-maps/>
- Centers for Medicare & Medicaid Services. "National Health Expenditure Data." Updated annually. <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data>
- Food and Drug Administration. "Office of Generic Drugs Annual Report." Annual. <https://www.fda.gov/drugs/generic-drugs/office-generic-drugs-annual-reports>
- Drug Enforcement Administration. "Aggregate Production Quotas." Annual. <https://www.deadiversion.usdoj.gov/quotas/>
- Substance Abuse and Mental Health Services Administration. "National Survey on Drug Use and Health (NSDUH)." Annual. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health>

### Congressional Reports

- Congressional Research Service. "Prescription Drug Monitoring Programs." Report R42593 (Updated 2024). <https://crsreports.congress.gov/>
- Congressional Research Service. "Pharmacy Benefit Managers and the Prescription Drug Supply Chain." Report R47412 (2024). <https://crsreports.congress.gov/>
- Government Accountability Office. "Drug Safety: FDA Has Improved Its Foreign Drug Inspection Program, but Needs to Assess the Effectiveness of Its Activities." GAO-23-105527 (2023). <https://www.gao.gov/>
- Congressional Budget Office. "Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid." (2023). <https://www.cbo.gov/>

### Agency Data Portals

- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book> - Patent and exclusivity data for all approved drugs
- CMS. Open Payments Database. <https://openpaymentsdata.cms.gov/> - All pharmaceutical industry payments to physicians
- DEA. Automation of Reports and Consolidated Orders System (ARCOS). <https://www.deadiversion.usdoj.gov/arcos/> - Controlled substance distribution data
- CDC. Wide-Ranging Online Data for Epidemiologic Research (WONDER). <https://wonder.cdc.gov/> - Drug overdose mortality data

---

## Books

- Macy, B. *Dopesick: Dealers, Doctors, and the Drug Company That Addicted America*. Little, Brown and Company, 2018. - Investigative account of the opioid crisis focused on Purdue Pharma and Appalachian communities
- Keefe, P. R. *Empire of Pain: The Secret History of the Sackler Dynasty*. Doubleday, 2021. - Comprehensive history of the Sackler family and Purdue Pharma's role in the opioid epidemic
- Posner, G. *Pharma: Greed, Lies, and the Poisoning of America*. Avid Reader Press, 2020. - Analysis of pharmaceutical industry business practices and regulatory failures
- Lexchin, J. *Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State*. University of Toronto Press, 2016. - Comparative analysis of Canadian pharmaceutical regulation
- Goldacre, B. *Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients*. Faber & Faber, 2012. - Analysis of pharmaceutical industry influence on clinical evidence and prescribing

---

## Think Tank Analysis

### Research Organizations

- Kaiser Family Foundation. "An Overview of the Medicare Part D Prescription Drug Benefit." 2024. <https://www.kff.org/medicare/fact-sheet/an-overview-of-the-medicare-part-d-prescription-drug-benefit/> - Comprehensive Part D program analysis
- Brookings Institution. "Reforming Pharmacy Benefit Managers to Reduce Drug Costs." 2024. <https://www.brookings.edu/> - Policy proposals for PBM reform
- Commonwealth Fund. "U.S. Health Care from a Global Perspective." 2024. <https://www.commonwealthfund.org/> - International comparisons including drug pricing
- AARP Public Policy Institute. "Rx Price Watch Report." Annual. <https://www.aarp.org/ppi/> - Tracking brand-name and generic drug price trends

### Policy Briefs

- USC Schaeffer Center for Health Policy & Economics. "The Role of Pharmacy Benefit Managers in Drug Pricing." 2024. <https://healthpolicy.usc.edu/>
- Manatt Health. "State Drug Importation Programs: Progress and Challenges." 2024. <https://www.manatt.com/health>
- West Health Policy Center. "Policy Proposals to Reduce Prescription Drug Costs." 2024. <https://www.westhealth.org/>

---

## Organizations and Advocacy Groups

| Organization | Focus | Type | Website |
|--------------|-------|------|---------|
| Patients for Affordable Drugs | Drug pricing reform advocacy | Patient advocacy | <https://www.patientsforaffordabledrugs.org/> |
| National Community Pharmacists Association (NCPA) | Independent pharmacy advocacy, PBM reform | Trade association | <https://www.ncpa.org/> |
| Association for Accessible Medicines (AAM) | Generic and biosimilar pharmaceutical industry | Trade association | <https://accessiblemeds.org/> |
| PhRMA | Brand-name pharmaceutical industry | Trade association | <https://www.phrma.org/> |
| PCMA (Pharmaceutical Care Management Association) | PBM industry | Trade association | <https://www.pcmanet.org/> |
| National Alliance of State Pharmacy Associations (NASPA) | State pharmacy regulatory issues | Professional association | <https://naspa.us/> |
| PDMP Training and Technical Assistance Center (TTAC) | PDMP implementation and best practices | Technical assistance | <https://www.pdmpassist.org/> |
| National Pain Advocacy Center | Chronic pain patient rights | Patient advocacy | <https://nationalpain.org/> |
| Academy of Integrative Pain Management | Non-opioid pain treatment | Professional association | <https://integrativepain.org/> |

---

## Data Sources

| Dataset | Provider | Update Frequency | URL | Description |
|---------|----------|------------------|-----|-------------|
| Opioid Dispensing Rate Maps | CDC | Annual | <https://www.cdc.gov/drugoverdose/rxrate-maps/> | State and county-level opioid prescribing rates |
| Open Payments | CMS | Annual | <https://openpaymentsdata.cms.gov/> | Pharmaceutical industry payments to physicians and hospitals |
| FDA Orange Book | FDA | Monthly | <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book> | Patent and exclusivity data for approved drugs |
| National Health Expenditure Data | CMS | Annual | <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data> | Total prescription drug spending by category |
| NSDUH | SAMHSA | Annual | <https://www.samhsa.gov/data/> | Substance use disorder prevalence and treatment access |
| ARCOS | DEA | Annual | <https://www.deadiversion.usdoj.gov/arcos/> | Controlled substance distribution by drug, state, and registrant type |
| Medicare Part D Drug Spending Dashboard | CMS | Annual | <https://www.cms.gov/data-research/statistics-trends-and-reports/information-products-and-data-tools> | Part D spending by drug, manufacturer, and beneficiary |

---

## News and Journalism

### Investigative Reports

- *STAT News*. "The Opioid Files." Ongoing investigative series. <https://www.statnews.com/> - Deep reporting on opioid crisis, pharmaceutical industry, and drug regulation
- *The Washington Post*. "The Opioid Files: DEA and Distributors." 2017-2023. <https://www.washingtonpost.com/graphics/investigations/dea-pain-pill-database/> - Landmark investigation into DEA enforcement failures and distributor conduct
- *Kaiser Health News*. "PBM Investigation Series." 2022-2024. <https://kffhealthnews.org/> - Reporting on PBM business practices and their impact on pharmacies and patients
- *ProPublica*. "Dollars for Docs." <https://projects.propublica.org/docdollars/> - Interactive database of pharmaceutical industry payments to physicians

### Ongoing Coverage

- *STAT News*. Pharmaceutical industry and drug policy coverage. <https://www.statnews.com/> - Leading daily publication covering pharmaceutical industry, FDA, and drug policy
- *Drug Channels*. PBM and drug distribution industry analysis. <https://www.drugchannels.net/> - Industry insider analysis of pharmaceutical distribution economics
- *Pink Sheet (Informa Pharma Intelligence)*. FDA regulatory intelligence. <https://pink.pharmaintelligence.informa.com/> - Detailed FDA regulatory and policy tracking

---

## International Sources

- OECD. "Health at a Glance: Pharmaceutical Expenditure." Annual. <https://www.oecd.org/health/health-at-a-glance/> - Cross-country pharmaceutical spending and pricing data
- World Health Organization. "WHO Model List of Essential Medicines." <https://www.who.int/medicines/publications/essentialmedicines/en/> - International standard for essential medication access
- PMPRB (Patented Medicine Prices Review Board, Canada). "Annual Report." <https://www.canada.ca/en/patented-medicine-prices-review.html> - Canadian drug price regulation methodology and outcomes
- NICE (National Institute for Health and Care Excellence, UK). "Technology Appraisals." <https://www.nice.org.uk/> - UK health technology assessment methodology and drug value determinations

---

## Legal Resources

### Case Law

- *FTC v. Actavis*, 570 U.S. 136 (2013) - Supreme Court held that pay-for-delay patent settlements can violate antitrust law, subjecting them to rule-of-reason scrutiny
- *Caraco Pharmaceutical Laboratories v. Novo Nordisk*, 566 U.S. 399 (2012) - Addressed Orange Book patent listing accuracy and generic manufacturers' ability to challenge incorrect use codes
- *Pharmaceutical Research and Manufacturers of America v. HHS* (multiple lawsuits filed 2023-2024) - Industry challenges to the Inflation Reduction Act's Medicare negotiation provisions on constitutional grounds (takings, compelled speech, due process)
- *Ohio v. American Medical Collection Agency* (ongoing) - Implications for prescription data security and PDMP data governance

### Statutory References

- 21 U.S.C. Chapter 9 -- Federal Food, Drug, and Cosmetic Act (core FDA authority)
- 21 U.S.C. Chapter 13 -- Controlled Substances Act (DEA scheduling and registration authority)
- 42 U.S.C. Section 1395w-111 through 1395w-116 -- Medicare Part D prescription drug benefit
- Public Law 117-169 -- Inflation Reduction Act of 2022, Title XI (drug pricing provisions)
- Public Law 115-271 -- SUPPORT for Patients and Communities Act of 2018
- 21 U.S.C. Section 384 -- Importation of prescription drugs (Section 804 of FD&C Act)

---

## Document Navigation

- Up: [Drugs Overview](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
